# Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct06281899` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06281899](<https://clinicaltrials.gov/study/NCT06281899>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06281899

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06281899. Randomized; no masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06281899, source copy `cardio:ctgov-nct06281899-2026-10-28`, retrieved 2026-10-31)
- Started: 2022-01-01 (actual) (ClinicalTrials.gov record NCT06281899, source copy `cardio:ctgov-nct06281899-2026-10-28`, retrieved 2026-10-31)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT06281899, source copy `cardio:ctgov-nct06281899-2026-10-28`, retrieved 2026-10-31)
- Completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT06281899, source copy `cardio:ctgov-nct06281899-2026-10-28`, retrieved 2026-10-31)
- Countries: Romania (ClinicalTrials.gov record NCT06281899, source copy `cardio:ctgov-nct06281899-2026-10-28`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06281899-2026-10-28`, retrieved 2026-10-31)

## The registry's words

- Brief title: Effect of Low Protein Diet on Top of Dapagliflozin on Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus
- Acronym: PRODAPA-CKD
- Condition: Chronic Kidney Diseases
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Dapagliflozin 10 mg Tab
- Intervention (Behavioral): Low protein diet
- Lead sponsor: Anemia Working Group Romania
- Lead sponsor class: OTHER
- Collaborator: Sf Ioan Emergency Clinical Hospital, Nephrology and Dialysis Department, Bucharest, Romania
- Collaborator class: UNKNOWN
- Collaborator: Dr Carol Davila Teaching Hospital of Nephrology, Nephrology Department, Bucharest, Romania
- Collaborator class: UNKNOWN
- Collaborator: Carol Davila University of Medicine and Pharmacy
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)

## Provenance

Content hash: 5c8e7e485bcee1ca5cf9e0767526de47de482dac9d60541c8f6aa2a9571e2997
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
